Physician profile
Nancy Smith
NPI 1639452121
$3,298.62
in general payments reported to CMS, 2019-2025
29 companies · $556 in 2025
The $556 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $1,364 · 2023: $652 · 2024: $568 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $18.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.46 |
| Education | $18.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $426.37 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $364.10 | 2022-2023 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $350.10 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $319.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $168.40 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $164.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $156.00 | 2022-2024 | Jynarque, Rexulti |
| Vifor Pharma, INC. | $152.82 | 2022-2023 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $147.90 | 2022-2023 | Rayaldee |
| Akebia Therapeutics INC | $133.31 | 2022-2023 | Auryxia |
| Lilly USA, LLC | $113.49 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $94.80 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $84.43 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.85 | 2024 | Jardiance |
| Pfizer INC. | $79.10 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $71.06 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.86 | 2022 | |
| Phathom Pharmaceuticals, INC. | $44.24 | 2024-2025 | Voquezna |
| Amgen INC. | $43.52 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $37.70 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $33.07 | 2023 | Benlysta, Jesduvroq |
| Kowa Pharmaceuticals America, INC. | $30.17 | 2025 | Zoryve |
| Travere Therapeutics, INC. | $29.40 | 2023 | |
| Shield Therapeutics INC | $24.81 | 2024 | |
| Boston Scientific Corporation | $24.23 | 2024 | Watchman Access System |
| Abbott Laboratories | $22.99 | 2024 | Eterna |
| Ani Pharmaceuticals, INC. | $21.10 | 2022 | |
| Calliditas Therapeutics US INC. | $20.59 | 2022 | |
| Astellas Pharma US INC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.